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Bypass of the need for metabolic activation by treating cells 
with the corresponding reactive PAH-diol-epoxide metabo-
lites resulted in similar adduct levels in all cell lines, which 
confirms that the influence of p53 is on the metabolism of 
the parent PAHs. Western blotting showed that CYP1A1 
protein expression was induced to much greater extent in 
TP53(+/+) cells than in the other cell lines. CYP1A1 is 
inducible via the aryl hydrocarbon receptor (AHR), but we 
did not find that expression of AHR was dependent on p53; 
rather, we found that BaP-induced CYP1A1 expression 
was regulated through p53 binding to a p53 response ele-
ment in the CYP1A1 promoter region, thereby enhancing 
its transcription. This study demonstrates a new pathway 
for CYP1A1 induction by environmental PAHs and reveals 
an emerging role for p53 in xenobiotic metabolism.
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Introduction
The TP53 tumour suppressor gene, which encodes the pro-
tein p53, is mutated in over 50 % of human tumours and 
is one of the most important cancer genes (Olivier et al. 
2010). p53, often described as the guardian of the genome, 
is involved in multiple cellular functions; amongst these 
is the response to cellular stress induced by various types 
of DNA damage, thereby delaying DNA synthesis or cell 
division to allow DNA repair or inducing apoptosis. In nor-
mal, unstressed cells, p53 protein expression is kept low 
via ubiquitin-mediated proteolysis that is regulated by the 
E3 ubiquitin ligase MDM2. Disruption of the normal p53 
response by TP53 mutation leads to the development of 
tumours. Besides acquired somatic mutations in the TP53 
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gene being a common feature of the cancer genotype, 
germline mutations can cause predisposition to a wide 
spectrum of early onset cancers associated with the Li–
Fraumeni and Li–Fraumeni-like syndromes (Olivier et al. 
2010). Furthermore, some TP53 polymorphisms in coding 
and noncoding regions have been shown to increase can-
cer susceptibility and to modify cancer phenotypes in TP53 
mutation carriers (Whibley et al. 2009). In addition to its 
role in the DNA damage response, p53 has also been found 
to regulate metabolic pathways such as glycolysis and oxi-
dative phosphorylation thereby linking p53 not only to can-
cer, but also to other diseases such as diabetes and obesity, 
and to other physiological processes such as ageing (Mad-
docks and Vousden 2011). Thus, the repertoire of genes 
subject to p53 control as a master regulatory transcription 
factor extends across a diverse group of biological activities 
(Menendez et al. 2009). It has also been observed that abro-
gation of p53 activity by knockout or knockdown of TP53 
in human cells in vitro affects carcinogen activation (Hock-
ley et al. 2008; Simoes et al. 2008) and drug metabolism 
(Goldstein et al. 2013), but as yet little is known about the 
mechanism of this phenomenon.
Polycyclic aromatic hydrocarbons (PAHs) are formed by 
the incomplete combustion of organic matter (Baird et al. 
2005; IARC 2010) and are widely distributed in the envi-
ronment. Several of them are highly carcinogenic, includ-
ing benzo[a]pyrene (BaP), the most widely studied, as well 
as dibenz[a,h]anthracene (DB[a,h]A) and dibenzo[a,l]
pyrene (DB[a,l]P) (Chang et al. 2013; Crowell et al. 2014; 
Lemieux et al. 2011; Siddens et al. 2012). PAHs require 
metabolic activation in order to exert their genotoxic 
effects (Baird et al. 2005; Luch and Baird 2005). Meta-
bolic activation is catalysed predominantly by cytochrome 
P450-dependent monooxygenases (CYPs) resulting in 
highly reactive diol-epoxides capable of forming covalent 
DNA adducts that can lead to mutations through errors in 
DNA replication (Phillips 2005).
In previous studies, we observed that many of the gene 
expression changes induced by BaP in human cells in vitro 
were in genes linked to pathways of p53 function (Hockley 
et al. 2006, 2008). Furthermore, we found that DNA adduct 
formation by BaP was significantly diminished in cells in 
which TP53 was knocked out or silenced (by siRNA inhi-
bition) relative to cells with normal p53 function (Hockley 
et al. 2008).
In order to evaluate the impact of the cellular TP53 status 
on the metabolic activation of a variety of different PAHs, 
a panel of isogenic human HCT116 cell lines that differ 
only with respect to their endogenous TP53 status, express-
ing either wild-type (WT) p53 [TP53(+/+)], heterozy-
gous p53 [TP53(+/−)] or mutant p53 [TP53(R248W/+) 
or TP53(R248W/−)], or with a complete knockout of 
p53 [TP53(−/−)] (Sur et al. 2009) was treated with BaP, 
DB[a,h]A) or DB[a,l]P. PAH-DNA adduct formation was 
determined by 32P-postlabelling. Expression of xenobiotic 
metabolising enzymes (XMEs) involved in PAH metabo-
lism (e.g. CYP1A1) was determined by Western blotting 
and qRT-PCR. Cells were also treated with the reactive 
PAH-diol-epoxides in order to bypass the need for meta-
bolic activation. We investigated whether p53 impacts on 
the regulation of XME expression such as CYP1A1 via the 
aryl hydrocarbon receptor (AHR) or whether the expres-
sion of XMEs such as CYP1A1 may be transcriptionally 
regulated by direct binding of p53 to the regulatory regions 
of the XME genes (Goldstein et al. 2013).
Materials and methods
Carcinogens
Benzo[a]pyrene (BaP; CAS no. 50-32-8; purity ≥96 %) 
was obtained from Sigma-Aldrich and (±)-anti-benzo[a]
pyrene-trans-7,8-dihydrodiol-9,10-epoxide (BPDE) was 
synthesized as reported previously (Hockley et al. 2008). 
Dibenz[a,h]anthracene (DB[a,h]A; CAS no. 53-70-3; 
purity ≥99.9 %), dibenzo[a,l]pyrene (DB[a,l]P; CAS 
no. 191-30-0; purity ≥99.9 %), (±)-anti-3,4-dihydroxy-
1,2-epoxy-1,2,3,4-tetrahydro-DB[a,h]A (DB[a,h]ADE) 
and (±)-anti-11,12-dihydroxy-13,14-epoxy-11,12,13,14-
tetrahydro-DB[a,l]P (DB[a,l]PDE) were synthesized at 
the Biochemical Institute for Environmental Carcinogens, 
Prof. Dr. Gernot Grimmer-Foundation, Germany, according 
to the literature methods (Platt and Oesch 1981; Lee and 
Harvey 1980; Karle et al. 1977; Luch et al. 1994). The BaP 
metabolites (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]
pyrene (BaP-t-7,8-dihydrodiol) and (±)-r-7,t-8,t-9,c-10-tet-
rahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BaP-tetrol-
I-1) were also synthesized at the Biochemical Institute for 
Environmental Carcinogens using earlier published meth-
ods (Platt and Oesch 1983; Yagi et al. 1977). Mass spec-
trometry data and high field 1H-NMR spectra (400 MHz) 
were in essential agreement to those published previously.
Cell culture and chemical treatment
Through targeted homologous recombination, a panel of 
isogenic HCT116 human colorectal carcinoma cell lines 
has been developed that differ only with respect to their 
endogenous TP53 status. Cells expressing either WT p53 
[i.e. TP53(+/+)], heterozygous p53 [i.e. TP53(+/−)], 
mutant p53 [i.e. TP53(R248W/+) or TP53(R248W/−)] or 
with a complete knockout of p53 [i.e. TP53(−/−)] (Sur 
et al. 2009) were kindly provided by Prof. Bert Vogelstein, 
John Hopkins University School of Medicine, Baltimore, 
MD. The R248 W mutation is found in some patients with 
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the Li–Fraumeni syndrome and leads to substitution of 
arginine for tryptophan, which results in modulated DNA 
binding capacity of the corresponding p53 protein product.
HCT116 cells were grown as adherent monolayers in 
complete growth medium: Dulbecco’s modified Eagle’s 
medium (#21885-025, Invitrogen) with 10 % foetal bovine 
serum (#10106, Invitrogen), supplemented with 100 units/
mL penicillin–streptomycin. Cells were cultured at 37 °C in 
5 % CO2 and passaged before the cells surpassed 80 % con-
fluence. For treatment, cells were seeded at 3 × 104 cells/
cm2 in flasks, grown for 48 h and subsequently treated with 
the test compounds or solvent dimethyl sulfoxide (DMSO) 
as a control for up to 48 h. The DMSO concentration was 
always kept at ≤0.5 % of the total culture medium volume. 
Based on previous experiments (Hockley et al. 2008), cells 
were treated with 2.5 µM BaP, DB[a,h]A or DB[a,l]P. Incu-
bations with PAH-diol-epoxides were as follows: 0.5 µM 
BPDE, 0.5 µM DB[a,h]ADE or 0.0025 µM DB[a,l]PDE. 
Cells were harvested by trypsinization and washed with 
phosphate-buffered saline (PBS).
In experiments using nutlin-3a (Cayman Chemicals; 
18585), cells were pretreated with 5 µM nutlin-3a for 6 h 
prior to exposure to BaP for 24 h. Nutlin-3a remained for 
the whole incubation period.
Cell viability and DNA adduct analysis
Cell viability (% control) was measured using the CASY 
Model TT Electronic Cell Analyser (Innovatis AG, Ger-
many). DNA was isolated from PAH-treated cells using a 
standard phenol/chloroform extraction method. The nucle-
ase P1 digestion enrichment version of the thin-layer chro-
matography (TLC) 32P-postlabelling assay was used to 
measure DNA adduct formation. The procedure was essen-
tially carried out as described previously (Arlt et al. 2008; 
Malik et al. 2013; Phillips and Arlt 2007; Siddens et al. 
2012). After chromatography, TLC sheets were scanned 
using a Packard Instant Imager (Dowers Grove, IL, USA) 
and DNA adduct levels (RAL, relative adduct labelling) 
were calculated from the adduct cpm, the specific activity 
of [γ-32P]ATP and the amount of DNA (pmol of DNA-P) 
used.
Western blot analysis
After treatment cells were lysed [62.5 mM Tris (pH 
6.8), 1 mM EDTA (pH 8.0), 2 % sodium dodecyl sul-
phate (SDS), 10 % glycerol], cells were sonicated and 
centrifuged for 5 min at 5,000 rpm. Subsequently, pro-
tein concentration of the supernatant was determined 
using the BCA Protein Assay (Pierce, Thermo Scien-
tific, UK) according to the manufacturer’s instructions. 
β-Mercaptoethanol (0.1 % final; in a solution containing 
the loading dye bromophenol blue) was added to reduce 
disulphide bonds and lysates were denatured at 95 °C 
for 5 min. Equal amounts of protein (10–20 µg) were 
separated by SDS–polyacrylamide gel electrophore-
sis (SDS-PAGE) using 4–12 % Bis–Tris gradient or 
10 % Bis–Tris gels, and Western blotted as previously 
reported (Kucab et al. 2012). After blocking in 3 % 
nonfat milk (dissolved in PBS with 0.2 % Tween-20), 
blots were incubated overnight at 4 °C with primary 
antibodies or anti-serum diluted in blocking solution. 
The following primary antibodies and dilutions were 
used: anti-p53 1:2,000 (Ab-6, Calbiochem), anti-p21 
(CDKN1A) 1:2,000 (556431, BD Pharmingen), anti-
NQO1 1:10,000 (ab34173, Abcam) and anti-AHR 
1:1,000 (ab2770, Abcam). Anti-CYP1A1 raised in rab-
bits against purified human recombinant CYP1A1 was 
a generous gift from Prof. F. Peter Guengerich (Vander-
bilt University, USA) and was diluted 1:4000. The anti-
body to detect β-actin 1:20,000 (ab6276, Abcam) was 
used as loading control. The secondary horseradish per-
oxidase-linked antibodies were as follows: anti-mouse 
(#170-5047; 1:10,000) and anti-rabbit (#170-5046; 
1:10,000) from BioRad.
Measurement of nucleotide excision repair (NER) capacity
To assess NER capacity in HCT116 cells, a modified 
comet assay was applied (Langie et al. 2006). This assay 
measures the ability of NER-related enzymes that are pre-
sent in the cell extract to incise substrate DNA containing 
BPDE-DNA adducts. The substrate nucleoids were pre-
pared from untreated HCT116 TP53(+/+) cells as reported 
(Langie et al. 2006). They were then exposed to BPDE 
(1 µM) or vehicle control (DMSO, 0.5 % in PBS) for 
30 min. Preparation of the protein extracts of the HCT116 
TP53(+/+), TP53(+/−), TP53(−/−), TP53(R248W/+) 
and TP53(R248W/−) cells, ex vivo repair incubation and 
electrophoresis were performed according to the published 
protocol (Langie et al. 2006). Dried slides were stained 
with ethidium bromide (10 µg/mL), and comets were ana-
lysed using a Leica fluorescence microscope (Leica DMLB 
020-519-010 LB30T). DNA damage was scored using the 
Comet IV capture system (version 4.11; Perceptive Instru-
ments, UK). Fifty nucleoids were assessed per slide and 
each sample was analysed in duplicate. All samples were 
measured blindly. The results from both replicates were 
combined for further analysis. The tail intensity (% tail 
DNA), defined as the percentage of DNA migrated from 
the head of the comet into the tail, was used as an indica-
tive measure of the repair capacity of the cell extracts. 
After subtracting background levels from all data, the final 
DNA repair capacity was calculated as previously reported 
(Langie et al. 2006).
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High-performance liquid chromatography (HPLC) analysis 
of BaP metabolites
For the analysis of BaP metabolites, culture medium (2 mL) 
from exposed cells was collected and stored at −20 °C 
until further processing. These samples were analysed at 
the National Institute of Occupational Health, Norway, as 
described (Dendele et al. 2014). Briefly, the medium was 
diluted to 10 mL with water, applied to a preconditioned 
(5 mL methanol and 10 mL water) Sep-Pak C18 cartridge 
(Millipore Corporation, Milford, MA, USA), followed by a 
wash with water (10 mL), and eluted with 100 % methanol 
(5 mL). The methanol eluate was evaporated to dryness at 
45 °C under a nitrogen stream and suspended in 100 μL 
of 100 % methanol. HPLC separation of BaP metabolites 
was performed on a Nova-Pak C18 3.9 × 150 mm2 column 
(Waters, Milford, MA, USA) with a Waters 625 LC Sys-
tem, equipped with a LC 240 fluorescence detector (Per-
kin-Elmer, Beaconsfield, UK) (Dendele et al. 2014). The 
BaP metabolites were separated with a linear gradient of 
30–100 % methanol in water for 40 min. For the quantita-
tive determination of BaP metabolites, the following fluo-
rescence conditions were used: 0 min, excitation 380 nm, 
emission 431 nm; 0.5 min, excitation 341 nm, emission 
381 nm; 20 min, excitation 253 nm, emission 410 nm; and 
27 min, excitation 380 nm, emission 431 nm. The concen-
trations of BaP metabolite standards dissolved in ethanol 
were determined by UV absorbance using extinction coef-
ficients supplied by the NIH Chemical Carcinogen Reposi-
tory (Midwest Research Institute, Kansas City, MO, USA).
In experiments using nutlin-3a, selected BaP metabolites 
were analysed at King’s College London. Briefly, 5 mL 
media was removed and extracted twice with 1 mL of ethyl 
acetate. Extracts were evaporated and taken up in 200 µL 
methanol, of which 20-µL aliquots were injected. HPLC 
analysis was performed using a HPLC Agilent 1100 Sys-
tem (Agilent Technologies) with a SunFireTM C18 reverse 
phase column (250 × 4.6 mm, 5 µm; Waters) using a meth-
anol/water gradient at a flow rate of 0.2 mL/min. A linear 
gradient of 20–100 % methanol over 10 min was followed 
by isocratic elution for 20 min. This was succeeded by a 
linear gradient of 100–20 % methanol for 10 min, and then 
isocratic elution of 20 % methanol for 5 min. Total run time 
was 60 min. The metabolites were analysed by fluores-
cence detection (excitation wavelength 375 nm, emission 
wavelength 450 nm). The two BaP metabolites analysed, 
BaP-t-7,8-dihydrodiol and BaP-tetrol-I-1, were identified 
using authentic standards.
Cell cycle
After treatment with 2.5 μM BaP for 24 and 48 h, HCT116 
cells were harvested and fixed in ice cold 70 % ethanol. 
For staining with propidium iodide (Invitrogen, UK), cells 
were pelleted, washed with PBS and resuspended in stain-
ing buffer containing 40 μg/mL propidium iodide, 100 μg/
mL RNase (Qiagen, UK) in PBS. Samples were incubated 
at 37 °C for 1 h in the dark and subsequently stored at 4 °C 
overnight before analysis. The DNA content of 10,000 cells 
per sample was analysed using a BD FACSCanto II (BD 
Biosciences, UK) at 488 nm.
Gene expression analysis
HCT116 cells were treated with 2.5 μM BaP for 24 h. RNA 
was isolated using RNeasy Mini kit (Qiagen, UK) and 
reverse-transcribed into cDNA using the SuperScript III 
reverse transcriptase kit (Invitrogen, UK). Relative quanti-
tation of CYP1A1 and CYP1B1 mRNA expression was per-
formed using fluorescent qRT-PCR with the ABI PRISM 
7500HT Fast Sequence Detection System (Applied Bio-
systems, UK) as described previously (Hockley et al. 2006, 
2008). CYP1A1 and CYP1B1 expression was detected using 
TaqMan® gene expression primers and probes (CYP1A1-
Hs00153120_m1 and CYP1B1-Hs00164383_m1). Rela-
tive gene expression was calculated using the comparative 
threshold cycle (CT) method.
Chromatin immunoprecipitation (ChIP)
HCT116 TP53(+/+) and TP53(−/−) cells were treated 
with 2.5 μM BaP for 24 h. In order to specifically induce 
p53 and its target p21, cells were also treated with 10 μM 
nutlin-3a. Cells underwent cross-linking (in 0.75 % for-
maldehyde for 10 min at room temperature) followed by 
quenching with glycine (in 0.125 M glycine for 5 min at 
room temperature). Cells were rinsed twice with 10 mL 
cold PBS, scraped and centrifuged (5 min, 1,000×g). Sub-
sequently, cells were lysed (50 mM HEPES–KOH pH 
7.5, 140 mM sodium chloride, 1 mM EDTA, 0.1 % SDS, 
1 % Triton X-100, 0.1 % sodium deoxycholate, and 1 % 
protease inhibitors), sonicated to an average DNA frag-
ment length of 500 base pairs (6 × 15 s) and then centri-
fuged (15 min, 8 000×g, 4 °C). The chromatin solution 
was precleared by adding protein A beads (sc-2001, Santa 
Cruz Biotechnology) that were pre-absorbed with BSA and 
salmon sperm DNA for 1 h at 4 °C. Immunoprecipitation 
of chromatin was performed with 5 μL of polyclonal α-p53 
antibody (CM1, Cambridge Bioscience) or with nonrelevant 
rabbit anti-IgG (Abcam, ab46540) overnight at 4 °C. Immu-
noprecipitates were washed three times with washing buffer 
(20 mM Tris–HCl pH 8.0, 500 mM sodium chloride, 1 % 
Triton X-100, 2 mM EDTA pH 8.0, 0.1 % SDS, and 1 % 
protease inhibitors). Samples were treated with 2 µL RNase 
A (0.5 mg/mL) for 30 min (37 °C), followed by 30 µL pro-
teinase K (20 mg/mL) for 2 h, (37 °C). DNA was isolated 
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by phenol/chloroform extraction. qRT-PCR was performed 
as described above with each sample containing 5 µL of 
immunoprecipitated DNA; values were normalised for 1 % 
input values. Five independent experiments were performed.
ChIP primer sequences for the CDKN1A promoter (5′ 
p53 response element) were adapted from previous studies 
(Kaeser and Iggo 2002; Laptenko et al. 2011). ChIP primer 
sequences for the CYP1A1 promoter (5′ p53 response ele-
ment) were adapted from Rockefeller University (http://
linkage.rockefeller.edu/p53; 16 October 2012) and verified 
by bioinformatic analysis. Primers are in italics, TaqMan 
probes are in bold, and p53-binding sites (CDKN1A, 
CYP1A1) are underlined:
CDKN1A promoter:
CTGGACTGGGCACTCTTGTCCCCCAGGCTGAGC 
CTCCCTCCATCCCTATGCTGCCTGCTTCCCAG 
GAACATGCTTGGGCAGCAGGCTGTGGCTCT 
GATTGGCTTTCTGGCCGTCAGGAACATGTCC 
C A A C AT G T T G A G C T C T G G C ATA G A A G A 
GGCTGGTGGCTATTTTGTCCTTGGGCTGCCT 
GTTTTCAGGTGAGGAAGGG
CYP1A1 promoter:
AGCTTCAGGCTACTGCAAGGAACAACCAAG 
CTGAAGTCAGCTGCGGCAACCTGCTTTGTG 
CAGCGGCGGCCGGGGGGATGAGAAATTTGG 
TGCTCAATCATTCTTGTAGTGATTTATATTTTCT 
ACTTAAACTATAACTTGCATTTATGCTATATACATA 
AACAAGCCATGAAAGCATGCTACGTGAAAGAAG 
CCAGACACA
Results
Cell viability after PAH exposure
In the previous work, treatment with 2.5 μM BaP and 
0.5 μM BPDE was found to induce DNA adduct formation 
in HCT116 TP53(+/+) cells within a linear dose–response 
range (Hockley et al. 2008). The optimal concentrations of 
DB[a,h]A and DB[a,l]P were determined in initial experi-
ments to be similar to that of BaP (data not shown). Thus, 
HCT116 cells were treated with 2.5 μM BaP, DB[a,h]A or 
DB[a,l]P, which allowed direct comparison of the potency 
of each PAH to induce DNA adduct formation. Whereas 
DB[a,h]ADE could be tested at the same concentration as 
BPDE, the high cytotoxicity of DB[a,l]PDE meant that the 
selected concentration for treatment was 200-fold lower, at 
0.0025 μM. Under these treatment conditions, no impact 
on cell viability (>80 % relative to controls) was observed 
in any of the isogenic HCT116 cell lines after PAH expo-
sure for 24 and 48 h (Supporting Figure 2), which was in 
line with previous findings (Hockley et al. 2008).
Expression of DNA damage response proteins and cell 
cycle alteration after PAH exposure
Expression of DNA damage response proteins p53 and p21 
was assessed by Western blot analysis after BaP exposure 
for 24 and 48 h (Fig. 1). Each cell line displayed a time-
independent and treatment-independent level of p53 expres-
sion, except for TP53(−/−) cells which did not express 
p53 as expected. Equal expression levels were detectable in 
TP53(+/+), TP53(R248W/+) and TP53(R248W/−) cells 
(Fig. 1b), whereas p53 levels decreased in TP53(+/−) 
relative to TP53(+/+) cells (Fig. 1a). The p53 target p21 
was expressed in all cell lines, but no induction was found 
after BaP treatment compared with control (untreated) 
samples (Fig. 1). The highest p21 levels were observed 
in TP53(+/+) cells. Expression levels were reduced in 
TP53(+/−) cells and further reduced in TP53(−/−) cells 
(Fig. 1a). TP53(R248W/+) cells showed similar levels of 
p21 expression to TP53(−/−) cells, whereas hardly any p21 
expression was seen in TP53(R248W/−) cells (Fig. 1b).
As shown in Supporting Figure 3A, cell cycle param-
eters as measured by flow cytometry were modestly altered 
after 24 h in TP53(R248W/+) and TP53(R248W/−) rela-
tive to TP53(+/+) cells. After 48 h, BaP treatment had a 
marginal effect on cell cycle in TP53(+/+) cells relative to 
controls (Supporting Figure 3B), consistent with previous 
results (Hockley et al. 2008).
Formation of PAH-DNA adducts
PAH-DNA adduct formation after 24 and 48 h was deter-
mined by the 32P-postlabelling method (Fig. 2). After BaP 
and BPDE treatment (Fig. 2a, b), the DNA adduct pattern on 
TLC was qualitatively similar in all isogenic HCT116 cells, 
consisting of one single adduct spot, previously identified 
as 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (dG-N2-BPDE) (Arlt et al. 2008). 
DB[a,h]A treatment also resulted in the formation of one 
major adduct spot which corresponded to the adduct spot 
obtained after treatment with DB[a,h]ADE (Fig. 2c, d). 
Exposure to DB[a,l]P induced a pattern consisting of four 
major adduct spots (Fig. 2e), of which three were found 
after treatment with DB[a,l]PDE (i.e. spots 1–3; Fig. 2f). No 
DNA adducts were detected in controls (data not shown).
Quantitative analysis obtained by 32P-postlabelling 
revealed a time-dependent increase in DNA adduct for-
mation from 24 to 48 h after treatment with the parent 
PAH (Fig. 2a, c, e). In TP53(+/+) cells, adduct levels 
were ~twofold higher and up to 1.5-fold higher for the 
other cell lines at 48 h than at 24 h. Amongst the PAHs, 
the genotoxic potencies increased in the order DB[a,h]
A ≪ BaP < DB[a,l]P. Strikingly, PAH-induced DNA 
adduct levels were up to eightfold lower in TP53(−/−) 
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than in TP53(+/+) cells; the difference was ~eightfold for 
BaP, ~sixfold for DB[a,h]A and ~fourfold for DB[a,l]P. 
Interestingly, adduct levels in TP53(+/−) cells were almost 
the same as those found in TP53(−/−) cells. It is also note-
worthy that adduct levels in both mutant TP53 cell lines, 
TP53(R248W/+) and TP53(R248W/−), were manifoldly 
lower compared with TP53(+/+) cells, but generally ~1.5 
times higher than in TP53(−/−) cells.
In contrast, similar adduct levels in TP53(+/+) cells 
relative to all other cell lines were observed after treatment 
with BPDE (Fig. 2b). In line with this observation, adduct 
levels were also similar after DB[a,h]ADE or DB[a,l]PDE 
exposure in all cell lines (Fig. 2d, f). For all three PAH-diol-
epoxides, DNA adduct formation was lower after 48 h rela-
tive to 24-h treatment. It is also noteworthy that adduct lev-
els after shorter diol-epoxide exposure, namely 2 h, were 
similar in all cell lines (data not shown). More importantly, 
as PAH-diol-epoxides do not require metabolic activation 
to bind to DNA, these findings suggest that the differences 
in DNA adduct formation observed with the parent PAHs 
are the consequence of the different capacities of the cells 
to metabolically activate the PAHs. In other words, these 
results suggest that the cellular TP53 status impacts on the 
metabolic bioactivation of the parent PAHs.
CYP1A1 protein expression after PAH exposure
Bioactivation of many PAHs including BaP, DB[a,h]A and 
DB[a,l]P is catalysed by CYP1A1 (Baird et al. 2005; Luch 
and Baird 2005). To determine the impact of the cellular 
TP53 status in HCT116 cells on the CYP1A1-mediated meta-
bolic activation of the PAHs tested, CYP1A1 protein levels 
were determined by Western blotting after 24 and 48 h. As 
shown in Fig. 1, basal levels of CYP1A1 were low in all 
cell lines, but CYP1A1 was induced after PAH exposure. A 
striking finding was that CYP1A1 induction correlated with 
the PAH-induced DNA adduct levels in each cell line (com-
pare Fig. 2). In contrast, after BPDE exposure, for exam-
ple, no CYP1A1 induction was observed (Fig. 1). The lack 
of CYP1A1 induction after BPDE correlated with the find-
ing that BPDE exposure of the cells resulted in similar DNA 
adduct levels regardless of the TP53 status (compare Fig. 2b).
PAHs such as BaP, DB[a,h]A and DB[a,l]P can bind 
to and activate AHR (Hockley et al. 2007). Thus, the 
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Fig. 1  Western blot analysis of p53, p21 (CDKN1A), CYP1A1, 
AHR and NQO1 protein expression in isogenic HCT116 cells after 
exposure to various PAHs or BPDE. Cells were exposed to 2.5 μM 
BaP, 0.5 μM BPDE, 2.5 μM DB[a,h]A or 2.5 μM DB[a,l]P and har-
vested after the times indicated. a HCT116 TP53(+/+) cells com-
pared to TP53(+/−) and TP53(−/−) cells. b HCT116 TP53(+/+) 
cells compared to TP53(R248W/+) and TP53(R248W/−) cells. 
β-Actin protein expression was used as a loading control. Representa-
tive images of the Western blotting are shown; at least duplicate anal-
ysis was performed from independent experiments
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activated receptor is capable of modulating the expression 
of its target genes such as CYP1A1 (Hockley et al. 2007). 
As shown in Fig. 1, AHR expression in whole cell lysates 
decreased in all cell lines to the same extent after PAH 
exposure.
CYP1A1 and CYP1B1 mRNA expression after BaP 
treatment
RT-PCR is a sensitive and specific measure of gene expres-
sion (Hamouchene et al. 2011; Hockley et al. 2006) and was 
used to evaluate CYP1A1 and CYP1B1 expression changes in 
HCT116 cells treated with BaP for 24 h. Similar to the results 
obtained by Western blotting, CYP1A1 mRNA induction after 
BaP treatment was lower in all cells relative to TP53(+/+) 
cells (Fig. 3a) and correlated with BaP-DNA adduct forma-
tion in each cell line (compare Fig. 1a). Small alterations 
in CYP1B1 mRNA induction were found in some cell lines 
(Fig. 3b); again CYP1B1 expression was lower relative to 
TP53(+/+) cells in all other cell lines. However, the fold dif-
ferences appeared to be subtle, suggesting that any change in 
CYP1B1 expression may not significantly influence the dif-
ferences in BaP-DNA adduct levels observed in these cell 
lines.
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Fig. 2  DNA adduct levels (RAL, relative adduct labelling) detected 
by 32P-postlabelling in isogenic HCT116 cells after exposure to vari-
ous PAHs and their corresponding diol-epoxides. Cells were exposed 
to a 2.5 μM BaP, b 0.5 μM BPDE, c 2.5 μM DB[a,h]A, d 0.5 μM 
DB[a,h]ADE, e 2.5 μM DB[a,l]P or f 0.0025 μM DB[a,l]PDE and 
harvested after the times indicated. The values are the mean ± range 
of duplicate cell incubations; each DNA sample was analysed in 
duplicate in separate experiments. Statistical analysis was per-
formed by one-way ANOVA followed by the Tukey post hoc test 
[***p < 0.005, different from HCT116 TP53(+/+) cells]. Insets 
Autoradiographic profiles of DNA adducts formed in HCT116 cells 
after exposure; the origins, at the bottom left-hand corners, were cut 
off before exposure
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NQO1 protein expression after BaP treatment
As BaP-derivatives can also be metabolised by NAD(P)
H:quinone oxidoreductase (NQO1) (Luch and Baird 2005), 
we also determined NQO1 protein expression in HCT116 
cells after BaP exposure. It appears that a marginal induc-
tion of NQO1 protein levels was observed upon BaP treat-
ment after 48 h (Fig. 1). However, this induction was very 
small and independent of the cellular TP53 status.
Impact of cellular TP53 status on BaP metabolism
In order to obtain further insights into the effects of TP53 
status on BaP metabolism, BaP metabolites were analysed 
in the cell culture medium by HPLC analysis. A scheme 
showing the structures of BaP metabolites analysed is 
given in Supplementary Figure 4. As shown in Table 1, the 
levels of all BaP metabolites analysed in the TP53(+/+) 
cells were significantly higher than in all other cultures. 
For example, the level of BaP-t-7,8-dihydrodiol, a precur-
sor of BPDE, was ~fivefold higher in TP53(+/+) than in 
TP53(−/−) cell cultures. Overall, the levels of BaP metab-
olites formed by each cell line corresponded to the BaP-
DNA adduct levels observed in these cells.
Impact of p53 induction on BaP metabolism and CYP1A1 
expression
Nutlin-3a, an inhibitor of MDM2, was used to induce p53 in 
TP53(+/+) cells. Using Western blot analysis, it was found 
that p53 was induced upon nutlin-3a pre-treatment which 
subsequently led to an increase in CYP1A1 levels in cells 
co-exposed to BaP for 24 h (Fig. 4a). CYP1A1 protein levels 
were slightly induced in cells treated solely with nutlin-3a 
for up to 30 h. Similar experiments carried out in TP53(−/−) 
cells showed a marginal induction of CYP1A1 levels after 
treatment with BaP alone, but pre-treatment with nutlin-3a 
had no effect on CYP1A1 expression levels (Fig. 4a).
The p53/nutlin-3a-mediated induction of CYP1A1 in 
TP53(+/+) cells after BaP exposure also altered the forma-
tion of BaP metabolites. For these experiments, the formation 
of BaP-t-7,8-dihydrodiol and BaP-tetrol-II-1 was determined 
in the cell culture medium using HPLC analysis. These 
metabolites were chosen as they are, in the first case, precur-
sors of BPDE and, in the second case, one of the hydroly-
sis products of BPDE. As shown in Fig. 4b, c, the levels of 
both BaP metabolites increased in TP53(+/+) cells and co-
exposed to nutlin-3a and BaP relative to cells treated with BaP 
alone, indicating that p53 induction by nutlin-3a increases 
CYP1A1-mediated BaP metabolism. As seen before, the lev-
els of both BaP metabolites were lower in TP53(−/−) com-
pared with TP53(+/+) cells (Fig. 4b, c; compare Table 1). 
In TP53(−/−) cells, no change was observed for BaP-t-7,8-
dihydrodiol, whereas BaP-tetrol-I-1 was significantly higher 
in TP53(−/−) cells treated with nutlin-3a and BaP relative to 
cells treated with BaP alone, but the change was small.
Binding of p53 to the DNA-regulatory elements of p53 
(p53REs) in the promoter region of CYP1A1 after BaP 
exposure
After demonstrating that alterations in the cellular p53 lev-
els can impact on the CYP1A1-mediated metabolism of BaP 
and subsequent formation of BaP-DNA adducts, we wanted 
to explore the potential mechanism behind this phenomenon. 
It is well known that p53 induces gene expression of its tar-
get genes by binding to p53REs and thereby inducing their 
transcription (Menendez et al. 2009). Recent studies have 
indicated that p53 can induce gene expression of CYP3A4 
by binding to p53REs (Goldstein et al. 2013). Therefore, 
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Fig. 3  Gene expression of a CYP1A1 and b CYP1B1 in isogenic 
HCT116 cells after exposure to 2.5 μM BaP for 24 h. Total RNA was 
extracted and the mRNA levels of the indicated genes were analysed 
by qRT-PCR. Values represent the mean ± SD of three incubations; 
each sample was determined by three separate analyses. Statistical 
analysis was performed by one-way ANOVA followed by the Tukey 
post hoc test [* p < 0.05; ** p < 0.01; *** p < 0.005, different from 
HCT116 TP53(+/+) cells]
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we hypothesised that CYP1A1 expression may also be regu-
lated by p53. After in silico analysis of the regulatory region 
upstream of the CYP1A1 gene, a putative p53RE was identi-
fied. We used ChIP to investigate whether p53 can bind to the 
p53RE identified in the regulatory region of CYP1A1. In order 
to validate the efficiency of the ChIP assay, we confirmed that 
p53 binds to a known p53RE of CDKN1A (p21) (Kaeser and 
Iggo 2002; Laptenko et al. 2011), a downstream target of p53, 
in TP53(+/+) cells after treatment with nutlin-3a (Fig. 5a). 
No increase in binding was observed in the BaP treated com-
pared to the negative (mock) control or untreated TP53(+/+) 
cells. The lack of p53 binding to the p53RE of CDKN1A (p21) 
is in line with the Western blot analysis where no p21 induc-
tion was observed after BaP treatment in TP53(+/+) cells 
under the experimental conditions used (see Fig. 1).
Most importantly, as shown in Fig. 5b, p53 was able to 
bind to the p53RE of CYP1A1 as indicated by the enrich-
ment of this DNA segment in the p53-precipitated DNA, 
after both nutlin-3a and BaP treatments. Again, no increase 
in binding was observed in the negative (mock) control 
or in untreated TP53(+/+) cells. These results support a 
p53-dependent induction mechanism of CYP1A1, thereby 
promoting CYP1A1-mediated BaP metabolism and subse-
quent BaP-induced DNA adduct formation.
DNA repair capacity
Nucleotide excision repair (NER) is the main DNA 
repair pathway for the studied PAHs, and p53-dependent 
pathways affecting global NER have been identified (Ford 
2005; Sengupta and Harris 2005). In order to determine 
whether the cellular TP53 status impacted on NER in 
HCT116 cells, we phenotypically assessed NER capacity. 
Cell extracts from HCT116 cells were examined for their 
ability to repair BPDE-induced DNA adducts using a modi-
fied comet assay (Langie et al. 2006). Utilising this assay, 
we found that all HCT116 cell lines used in the present 
study had the same NER capacity (Supporting Figure 5).
Discussion
The repertoire of genes subject to p53 control extends 
across a diverse group of biological activities that include 
apoptosis, cell cycle regulation, senescence, energy metab-
olism, angiogenesis, cell differentiation and immune 
response. In this study, we show that carcinogenic PAHs 
can induce CYP1A1 in human cells via a p53-dependent 
mechanism, indicating a novel role for p53 in CYP1A1-
mediated carcinogen metabolism. CYP1A1 is one of the 
key enzymes involved in PAH metabolism, and we found 
that alterations of the cellular TP53 status as well as nut-
lin-3a-induced p53 activation had dramatic effects on the 
metabolism of a variety of PAHs, namely BaP, DB[a,h]A 
and DB[a,l]P.
Using a panel of isogenic colorectal HCT116 cells dif-
fering only with respect to their endogenous TP53 sta-
tus, we found that complete loss of p53 function resulted 
Table 1  HPLC analysis of BaP metabolites in HCT116 cell culture medium
a Structures of the BaP metabolites detected by HPLC are shown in Supplementary Figure 4
b Statistical analysis was performed by one-way ANOVA followed by Tukey post hoc test [* p < 0.05; *** p < 0.005, different from HCT116 
TP53(+/+) cells]
c BaP-tetrol-I-1: BaP-r-7,t-8,t-9,c-10-tetrahydrotetrol; BaP-tetrol-I-2: BaP-r-7,t-8,t-9,t-10-tetrahydrotetrol; BaP-tetrol-II-1: BaP-r-7,t-8,c-9,t-10-
tetrahydrotetrol; BaP-tetrol-II-2: BaP-r-7,t-8,c-9,c-10-tetrahydrotetrol
d ND not detected
BaP/BaP metabolitea pmol BaP/BaP metabolite (mean ± SD [n = 4])b
HCT116  
TP53(+/+)
HCT116  
TP53(+/−)
HCT116  
TP53(−/−)
HCT116 
TP53(R248W/+)
HCT116 
TP53(R248W/−)
BaP-t-7,8-dihydrodiol 63.2 ± 4.7 17.3 ± 0.8*** 13.3 ± 0.7*** 41.6 ± 3.8*** 34.6 ± 2.7***
BaP-c-7,8-dihydrodiol 0.6 ± 0.1 0.2 ± 0.1* 0.4 ± 0.3 0.5 ± 0.1 0.4 ± 0.1*
BaP-tetrol-I-1c 16.4 ± 1.5 0.7 ± 0.1*** 0.6 ± 0.1*** 2.8 ± 0.2*** 1.6 ± 0.2***
BaP-tetrol-I-2c 1.6 ± 0.1 0.4 ± 0.01*** 0.3 ± 0.03*** 0.8 ± 0.1*** 0.6 ± 0.1***
BaP-tetrol-II-1c 2.0 ± 0.1 0.1 ± 0.1*** 0.1 ± 0.1*** 0.4 ± 0.02*** 0.2 ± 0.1***
BaP-tetrol-II-2c 6.1 ± 0.2 1.1 ± 0.1*** 1.1 ± 0.1*** 2.8 ± 0.1*** 2.1 ± 0.2***
BaP-4,5-dihydrodiol 3.1 ± 0.3 1.1 ± 0.2*** 0.9 ± 0.1*** 1.8 ± 0.2*** 1.6 ± 0.4***
BaP-9,10-dihydrodiol 119.1 ± 4.7 21.6 ± 1.2*** 21.2 ± 2.0*** 52.7 ± 1.3*** 37.5 ± 4.0***
BaP-3-ol NDd 0.1 ± 0.1 0.1 ± 0.1 ND ND
BaP-9-ol 0.6 ± 0.1 0.4 ± 0.1*** 0.3 ± 0.01*** 0.2 ± 0.02*** 0.1 ± 0.01***
BaP 319.8 ± 35.7 483.3 ± 37.8*** 403.8 ± 28.2 447.8 ± 47.8* 579.5 ± 89.6***
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in considerably lower PAH-DNA adduct levels compared 
with cells having wild-type p53 (Fig. 1). This is in line with 
a previous observation using the HCT116 TP53(+/+) and 
TP53(−/−) cells exposed to BaP and where results were 
confirmed by knocking down TP53 in WT cells by siRNA 
(Hockley et al. 2008). Previous gene expression data sug-
gested that off-target effects of the TP53 knockout proce-
dure by homologous recombination in HCT116 cells were 
minimal at the gene expression level (Hockley et al. 2008). 
Furthermore, the same phenomenon was observed in other 
cell lines (e.g. lung A549 cells) with stably knocked down 
p53 expression, although the difference in adduct levels in 
cells with no p53 expression was greater (Hockley et al. 
2008). As this phenomenon was not observed after expo-
sure to the PAH-diol-epoxides (compare Fig. 2), these 
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Fig. 4  a Western blot analysis of p53 and CYP1A1 protein expres-
sion in HCT116 TP53(+/+) and TP53(−/−) cells after pre-treatment 
with nutlin-3a (5 μM) for 6 + 24 h and co-exposure with 2.5 μM 
BaP for 24 h. Representative images of the Western blotting are 
shown and duplicate analysis was performed from independent exper-
iments. HPLC analysis of BaP-t-7,8-dihydrodiol (b) and BaP-tetrol-
I-1 (c) in the culture medium of HCT116 TP53(+/+) and TP53(−/−) 
cells after pre-treatment with nutlin-3a (5 μM) for 6 + 24 h and co-
exposure with 2.5 μM BaP for 24 h. Values represent the mean ± SD 
of at least three separate incubations. Statistical analysis was per-
formed by one-way ANOVA followed by the Tukey post hoc test 
[**p < 0.01; ***p < 0.005, different from BaP treated only]
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Fig. 5  Binding of p53 to the DNA-regulatory elements (p53RE) of 
a CDKN1A and b CYP1A1 in HCT116 TP53(+/+) after exposure 
to 2.5 μM BaP for 24 h. HCT116 TP53(+/+) were also treated with 
nutlin-3a (10 μM) for 6 + 24 h. After chromatin immunoprecipita-
tion (ChIP) with anti-p53 antibody, the immunoprecipitated DNA 
was subjected to qRT-PCR using primers amplifying the indicated 
p53RE regions as outlined in the “Materials and methods”. Values 
represent the mean ± SD of at least three separate experiments. Sta-
tistical analysis was performed by one-way ANOVA followed by the 
Tukey post hoc test [*p < 0.05; ***p < 0.005, different from control 
(untreated)]
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results indicate that the levels of p53 expression impact on 
the metabolic activation of the parent PAH.
In the present study, we also showed that BaP metabo-
lites measured in the culture media were higher with 
HCT116 TP53(+/+) cells than with TP53(−/−) cells 
(Table 1). The measured metabolites included BaP-tetrols, 
BaP-dihydrodiols and hydroxylated-BaP metabolites dem-
onstrating that CYP-mediated metabolism was impaired 
in TP53(−/−) cells, which correlated with lower BaP-
DNA adduct formation in these cells. Higher induction of 
CYP1A1 expression (Fig. 3) and an increase in CYP1A1 
protein levels (Fig. 1) in HCT116 cells with WT p53 
explains the difference in BaP metabolism observed in 
TP53(−/−) cells. Furthermore, pre-treatment of HCT116 
TP53(+/+) cells with nutlin-3a led to p53 induction and 
subsequent stimulation of CYP1A1 expression after co-
exposure to BaP (Fig. 4a). Consequently, p53 induction by 
nutlin-3a enhanced CYP1A1-mediated BaP metabolism 
(Fig. 4b).
Many studies have demonstrated the induction of p53 in 
response to PAH exposure and this can be of significance 
for the molecular phenomenon (i.e. impact of TP53 status 
on PAH-induced DNA adduct formation) described above. 
We and others previously identified p53 as an important 
component of PAH-induced transcriptional responses in 
human cell lines and in vivo (Hamouchene et al. 2011; 
Hockley et al. 2006, 2008; Labib et al. 2012; Malik et al. 
2012, 2013). Thus, these gene–environment interactions 
need to be taken into account with regards to PAH metabo-
lism. Furthermore, as many anti-cancer treatment regimens 
are composed of several drugs of which at least one is a 
p53 activating drug, our molecular observation may also be 
of clinical importance (Goldstein et al. 2013). Therefore, 
these potential drug-environmental interactions may also 
be carefully considered for human risk assessment.
A well-established molecular mechanism for the induc-
tion of CYP1A1 is via AHR with 2,3,7,8-tetrachlorod-
ibenzo-p-dioxin (TCDD) being one of the best character-
ised ligands for this orphan nuclear receptor.(Wang et al. 
2011) PAHs such as BaP can also bind to and activate AHR 
thereby enhancing their own metabolic activation (Hock-
ley et al. 2007). However, a recent study has indicated that 
p53 can induce gene expression of certain CYPs by bind-
ing to p53REs in the promoter region of these CYPs. It was 
shown that p53 induces the activity of CYP3A4, one of the 
major drug-metabolising enzymes in the liver, via its bind-
ing to p53REs and the subsequent transcriptional enhance-
ment of CYP3A4 (Goldstein et al. 2013). In the present 
study, we propose a new mechanism by which CYP1A1 is 
induced by p53. Using ChIP analysis, we showed that p53 
can bind to a p53RE in the regulatory region upstream of 
the CYP1A1 gene in HCT116 TP53(+/+) cells after BaP 
exposure (Fig. 5). Consequently, these results indicate that 
BaP is able to induce CYP1A1 not only by binding as a 
ligand to AHR promoting CYP1A1 transcriptional activa-
tion, but also by induction of p53 which can subsequently 
trigger CYP1A1 transcription via its binding to p53REs.
Both complete and partial inactivation of tumour sup-
pressors such as TP53 can play a critical role in the patho-
genesis of cancer (Berger et al. 2011). It has been shown 
that reductions in p53 dosage and function can impact on 
a cell’s ability to respond to DNA damage (Berger et al. 
2011; Bunz et al. 1999). Deletions of the TP53 locus are 
frequently found in human cancer, and loss of heterozy-
gosity (LOH) has been shown to occur in a fraction of 
tumours harbouring a TP53 mutation (Berger and Pan-
dolfi 2011). TP53 is a powerful example of how haploin-
sufficiency promotes tumourigenesis, whereby loss of one 
copy of TP53 gives rise to a phenotype intermediate to that 
occurring after complete loss of the gene (Berger and Pan-
dolfi 2011). As such, survival of Trp53(+/−) mice show an 
intermediate survival to that Trp53(−/−) and Trp53(+/+) 
mice, and tumours that develop in Trp53(+/−) mice do 
not always display loss of the remaining WT allele (Berger 
et al. 2011; Venkatachalam et al. 1998). Therefore, it was 
expected that HCT116 TP53(+/−) cells generate an inter-
mediate response to those observed in TP53(−/−) and 
TP53(+/+) cells. Interestingly, HCT116 TP53(+/−) cells 
behaved more similar to TP53(−/−) cells than TP53(+/+) 
cells with regards to PAH-DNA adduct formation, while 
adduct formation induced by the corresponding PAH-diol-
epoxides again did not differ (Fig. 2). This observation was 
in accordance with the fact that HCT116 TP53(+/−) and 
TP53(−/−) cells formed similar amounts of BaP metabo-
lites (Table 1). Expression of CYP1A1, at both the gene 
and protein level (Figs. 1, 3), was also similar in both cell 
lines. These results suggest that in HCT116 TP53(+/−) 
cells, the remaining WT allele is not sufficient for normal 
cellular function. This possibility has been indicated in 
another study using these cells where loss of one WT allele 
resulted in a ~fourfold reduction in TP53 mRNA and pro-
tein levels compared with TP53(+/+) cells before and after 
p53 stabilization resulting from UV radiation (Lynch and 
Milner 2006). One reason for this phenomenon could be 
that p53 function is dependent on its tetrameric structure 
and reduction in dosage of the WT protein by 50 % may 
result in disproportionate reduction in active tetramer con-
centrations (Santarosa and Ashworth 2004).
The importance of p53 is also highlighted by the fact 
that it is mutated in over 50 % of human cancers (Olivier 
et al. 2010). Mutation patterns and spectra in TP53 have 
been linked to environmental exposures including PAHs 
(Arlt et al. 2007; Kucab et al. 2010). For example, lung 
tumours of tobacco smokers (but not of nonsmokers) con-
tain a high percentage of G to T transversions in TP53 at 
several hotspot locations (in particular, at codons 157, 
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158, 175, 245, 248 and 273) characteristic of PAHs pre-
sent in tobacco smoke.(Denissenko et al. 1996) Of note, 
hotspot mutations found at codons 175, 248, 249 and 273 
together account for over 25 % of all missense mutations 
identified in human cancers (Olivier et al. 2010). Mutant 
p53 expressed in preneoplastic and/or neoplastic cells can 
severely limit or abolish the capacity of p53 to regulate its 
target genes (Freed-Pastor and Prives 2012). One TP53 hot-
spot mutation found in human tumours, R248 W, has been 
identified as a contact mutation that induces conforma-
tional changes and abolishes the tumour suppressive activ-
ity of p53 (Song et al. 2007). Both in HCT116 cells where 
one WT allele was replaced with mutant (R248 W) allele, 
and in cells where one WT allele was inactivated by homol-
ogous recombination and the other was replaced with a 
mutant (R248 W) allele, PAH metabolism and PAH-DNA 
adduct formation was altered relative to TP53(+/+) cells 
(Table 1; Figs. 1, 2, 3). The response in HCT116 cells with 
mutant p53 was similar to that in cells having a complete 
knockout of p53. However, it is possible that cells carrying 
a different TP53 mutation may respond differently. A more 
comprehensive approach to studying the impact of distinct 
TP53 mutations in cells with a closely matched genetic 
background for comparative functional analysis of p53 and 
carcinogen metabolism in the future has been published 
recently (Odell et al. 2013; Wei et al. 2011).
The responses seen after PAH exposure in HCT116 cells 
with altered p53 expression have been similar for different 
compounds in this study, but the response to other envi-
ronmental carcinogens could be different. Another envi-
ronmental carcinogen which has been tested in HCT116 
TP53(+/+) and TP53(−/−) cells is aristolochic acid I 
(AAI), a herbal drug derived from the Aristolochia spe-
cies which is a potent human carcinogen involved in the 
development of aristolochic acid nephropathy and linked 
to urothelial cancer (Gokmen et al. 2013; Schmeiser et al. 
2014). The major activation pathway for AAI is nitroreduc-
tion, NQO1 being the most efficient activating enzyme, 
while CYP1A-mediated demethylation contributes to AAI 
detoxification (Stiborova et al. 2014). AAI-DNA adduct 
formation was significantly lower in TP53(−/−) relative 
to TP53(+/+) cells (Simoes et al. 2008). Interestingly, 
CYP1A1 gene expression measured by qRT-PCR analy-
sis was higher in TP53(−/−) compared with TP53(+/+) 
cells after AAI exposure (Simoes et al. 2008), suggesting 
that cellular TP53 status may impact on CYP1A1-mediated 
AAI detoxification. However, the mechanism by which 
TP53 status influences AAI metabolism and AAI-DNA 
adduct formation in human cells remains to be investigated 
further.
In contrast, DNA adduct formation by a nitroarene, 
3-nitrobenzanthrone (3-NBA), was similar in HCT116 
TP53(+/+) and TP53(−/−) cell lines (Hockley et al. 2008; 
Simoes et al. 2008). This observation indicates that the cel-
lular impact of p53 on carcinogen metabolism depends on 
the agent studied and/or that only certain XMEs depend on 
p53 function. The most efficient enzyme to activate 3-NBA 
to DNA adducts is NQO1 (Arlt et al. 2005, 2006; Stiborova 
et al. 2010). Thus, NQO1 seems to be an enzyme not influ-
enced by p53, which is in line with the fact that NQO1 pro-
tein expression was not altered in the HCT116 cell lines 
after BaP exposure (Fig. 2). Another recent study showed 
that induction of CYP2E1 gene expression is under the tran-
scriptional control of p53 (Leung et al. 2013). As CYP2E1 
overexpression inhibited migration of highly invasive 
MDA-MB-231 breast cancer cells expressing mutant p53, 
the authors concluded that manipulation of CYP2E1 protein 
expression could be potentially exploited in breast cancer 
therapy (Leung et al. 2013). However, in the context of our 
investigations, this study indicates that CYP2E1-mediated 
carcinogen metabolism may be altered by p53 expression 
and seems to be a promising target for future investiga-
tions. One typical substrate of CYP2E1 is ethanol which is 
the main cause of various liver diseases (Beier and McClain 
2010). Another recent study demonstrated that UDP-glu-
curonosyltransferase 2B7 (UGT2B7) expression is regu-
lated via the p53 pathway (Hu et al. 2014). Epirubicin, an 
anticancer drug, stimulated UGT2B7 promoter activity via 
p53RE in human hepatocarcinoma HepG2 cells and simi-
larly nutlin-3a enhanced UGT2B7 expression and recruited 
p53 protein to the UGT2B7 p53RE in these cells (Hu et al. 
2014). Collectively, these findings suggest a novel role for 
p53 in the regulation of both phase I and phase II XMEs.
In summary, we found that carcinogenic PAHs induce 
CYP1A1 expression in human cells via a p53-dependent 
mechanism. Thus, our identification of CYP1A1 as novel 
p53 target gene provides new insights into the mechanism 
controlling CYP1A1 expression. These results also provide 
new fundamental insights into the mechanism(s) of p53 in 
PAH-induced carcinogenesis. These results indicate that 
p53 may impact on the efficacy of chemotherapeutic drugs. 
However, they also indicate that gene–environment interac-
tions need to be taken into account with regards to carcino-
gen metabolism. Future investigations will need to clarify 
which other XMEs depend on p53 function and which 
other environmental carcinogens depend on p53 for their 
metabolic activation.
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